/

PALI

Palisade Bio, Inc.Closed

1.47−0.13 −7.86%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.54 +5.12%

Open

1.56

Prev close

1.59

Day range

1.461.58

52-week range

1.322.86

Volume

1.58M0.63×

Mkt cap

255.31M

P/E ttm

2.44

Fwd P/E

-5.16

EPS ttm

0.6000

Div yield

0.00%

Earnings

—

From 52w high

−48.78%

Price Chart

Yahoo Finance · delayed

PALIOct 13, 2026O 1.56H 1.58L 1.46C 1.47−0.12 (−7.55%)Vol 1.59M

SMA 501.86
SMA 2001.90

1Y change −26.50% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PALI Palisade Bio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.34%
1 month: −28.64%
3 months: −23.83%
6 months: −28.64%
Year to date: −37.45%
1 year: −20.54%

Valuation & ownership

Market cap: 255.31M
Enterprise value: 130.14M
P/E (ttm): 2.44
Forward P/E: -5.16
PEG ratio: —
Price / book: 2.09
Price / sales (ttm): 510.61
EV / EBITDA: -3.68
EPS (ttm): 0.6000
EPS (forward): -0.2838
Beta (5y monthly): 1.62
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 174.27M
Float: 135.43M
Short % of float: 17.80%
Short ratio (days): 8.47
Held by insiders: 4.16%
Held by institutions: 101.35%
Avg volume (3m): 2.50M
50-day average: 1.86
200-day average: 1.91
52-week change: −20.54%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 40.1
vs 50-day SMA: −20.77%
vs 200-day SMA: −22.73%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.51%
Realised vol (20d, ann.): 94.5%
From 52-week high: −48.60%
From 52-week low: +11.36%

ANR

Analyst Consensus

10 analysts

Consensus

Strong buy

1.30 on a 1 (strong buy) – 5 (sell) scale

Mean target

9.80

+568.94% implied

Low 5.00Median 7.50High 25.00

Recommendation trend

Now10 / 0 / 0
1m ago9 / 0 / 0

DES

About Palisade Bio, Inc.

Yahoo Finance profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Sector: Healthcare
Industry: Biotechnology
Employees: 14
Headquarters: Denver, CO, United States
Website: palisadebio.com
Officers: Mr. J. D. Finley CEO, CFO & Director
Dr. Mitchell Lawrence Jones M.D., Ph.D. President & Chief Medical Officer
Mr. Ramesh C. Donthamsetty C.F.A. Senior VP of Corporate Development & Investor Relations
Dr. Joerg Heyer Ph.D.

SEAS

Seasonality · PALI

2007–2026 · monthly returns

Strongest month Sep +7.40%Weakest month Aug −9.16%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-36.6	18.8	-1.1	14.3	6.0	-1.4	-9.1	2.6	-30.8	8.5			−37.7%
2025	-17.6	-39.0	-18.1	14.7	-5.1	-8.1	50.0	-33.3	26.5	140.7	1.9	11.4	+42.4%
2024	1.7	-33.3	0.0	0.5	-20.1	-6.6	-12.9	-9.9	0.6	-23.4	-9.6	-32.9	−81.4%
2023	-44.2	-25.5	63.0	-54.8	-17.0	28.8	32.9	-69.9	-14.7	-3.4	12.5	-6.3	−88.7%
2022	-7.7	-23.3	15.2	-26.4	-33.3	-21.2	-4.9	-59.0	-37.5	-10.0	-13.6	33.7	−92.0%
2021	67.0	-8.8	26.9	-25.4	-49.9	6.8	-28.0	-4.1	-5.7	3.4	-15.0	-44.2	−75.4%
2020	17.2	-19.8	-29.0	7.6	29.6	-21.7	12.5	-14.8	-15.9	-3.4	16.1	35.4	−11.1%
2019	38.7	9.3	-6.4	13.6	-10.0	-35.6	-62.1	-22.3	-2.3	-9.0	-42.8	13.8	−84.0%
2018	6.4	-17.5	9.3	0.0	1.2	-33.5	1.8	8.0	-12.3	-45.8	-13.8	-38.0	−82.0%
2017	-14.8	54.8	14.0	-10.2	-5.9	29.8	-73.2	-23.2	10.9	-8.3	-5.8	50.9	−51.0%
2016	-24.3	28.2	-25.0	-20.0	-43.3	-14.7	-17.2	16.7	14.3	-18.8	7.7	-3.6	−73.8%
2015	14.0	21.3	-49.5	-11.1	-8.9	26.0	-10.8	-15.6	-16.4	-3.3	-6.8	-6.4	−62.1%
2014	13.1	8.5	17.4	-14.1	19.4	-1.9	-32.2	42.3	-19.4	-16.2	2.2	-3.2	−6.5%
2013	12.8	-13.8	5.7	6.3	27.7	-2.0	6.7	6.9	59.4	-17.7	21.5	7.4	+167.0%
2012	6.2	11.7	-2.6	-11.6	0.0	-7.1	1.1	-31.2	95.3	-28.0	38.9	-12.8	+12.4%
2011	-8.0	5.1	-12.2	-0.6	-23.5	9.5	-24.0	12.3	1.6	1.5	-11.4	-17.1	−54.2%
2010	4.5	11.2	-1.4	42.9	1.4	-15.8	-2.0	-24.5	36.2	-11.5	-9.9	5.5	+18.4%
2009	5.5	-46.0	4.3	19.4	-10.3	-1.0	11.5	-5.2	42.7	-19.1	40.9	0.0	+8.5%
2008	-14.5	-0.9	-18.0	-30.1	-8.3	-11.4	6.1	14.7	-23.5	16.8	0.0	3.1	−55.8%
2007				20.3	-8.8	-21.7	-14.2	38.1	0.9	-6.1	-12.6	38.1	+16.6%

INSD

Insider Activity · PALI

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

10.01M shares

Sells, 6 months

198.7K shares

Net shares

+9.81M

Net change in insider shares

−382.40%

Date	Insider	Transaction	Shares	Value
Oct 5, 2026	Jones Mitchell LawrencePresident	—	2.62M	—
Oct 5, 2026	Finley John DavidChief Executive Officer	—	3.23M	—
Oct 1, 2026	Williams Donald AllenDirector	Purchase at price 1.42 - 1.46 per share.	20K	$28.80K
Aug 18, 2026	Finley John DavidChief Executive Officer	Stock Gift at price 0.00 per share.	88.4K	—
Jul 8, 2026	Baltera Robert F Jr.Director	Purchase at price 1.96 - 1.99 per share.	45K	$88.70K
Jul 6, 2026	Baltera Robert F Jr.Director	Purchase at price 2.03 - 2.05 per share.	50K	$102.08K
Jul 6, 2026	Finley John DavidChief Executive Officer	Sale at price 2.07 per share.	146.8K	$303.34K
Jul 6, 2026	Jones Mitchell LawrenceOfficer	Sale at price 2.05 per share.	51.9K	$106.54K
Jul 6, 2026	Finley John DavidChief Executive Officer	Conversion of Exercise of derivative security at price 0.70 per share.	335.3K	$93
Jul 5, 2026	Jones Mitchell LawrenceOfficer	—	131.2K	—
Jul 1, 2026	Baltera Robert F Jr.Director	Purchase at price 1.98 per share.	30K	$59.40K
Jun 9, 2026	Chuang EmilDirector	—	20.2K	—
Jun 9, 2026	Williams Donald AllenDirector	—	60.7K	—
Jun 9, 2026	Wei BinxianDirector	—	20.2K	—
Jun 9, 2026	Baltera Robert F Jr.Director	Stock Award(Grant) at price 0.00 per share.	336.9K	—
Jun 9, 2026	Williams Donald AllenDirector	Stock Award(Grant) at price 0.00 per share.	1.50M	—
Jun 9, 2026	Wei BinxianDirector	Stock Award(Grant) at price 0.00 per share.	592.3K	—
Jun 9, 2026	Chuang EmilDirector	Stock Award(Grant) at price 0.00 per share.	592.3K	—
Jun 9, 2026	Zwick Jordan MichaelDirector	Stock Award(Grant) at price 0.00 per share.	336.9K	—
Feb 11, 2026	Finley John DavidChief Executive Officer	Sale at price 1.75 per share.	3.9K	$6.82K

13F

Investors Holding PALI

latest 13F filings of 29 followed managers

Investors holding PALI
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$2.4M	0.00%	1.12M	−23%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PALI

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PALI

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Palisade Bio, Inc.

Seasonality · PALI

Insider Activity · PALI

Congress Trades · PALI

Investors Holding PALI

Investors Holding PALI

Congress Trades · PALI

Insider Activity · PALI

Seasonality · PALI

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Palisade Bio, Inc.

Financial Snapshot

Earnings & Dividends

News